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INTRODUCTION
Obstetric and gynecological hemorrhage remains 
a frequent and severe complication that affects women 
at childbearing age and at the period of their full physical 
and professional activity. This problem applies to women in 
both developing and industrial countries. In the latter ones, 
including Poland, it is a result of constantly increasing rate 
of caesarean deliveries, accompanied by a several times 
higher risk of peripartum hemorrhage. For the experts from 
the World Health Organization there is a target to limit the 
global maternal mortality ratio from 216 per 100 000 live 
births in 2015 to 70 per 100 000 live births in 2030 (World 
Health Statistics 2018. Indicator 3.1.1). Decrease in the in-
cidence of severe hemorrhages and their consequences 
can be achieved through providing medical care by the 
health care professionals who have knowledge about the 
causes, pathomechanism and pharmacotherapy of these 
complications. It is known, that the development, imple-
mentation and compliance with management algorithms 
for severe hemorrhages contributes to a significant reduc-
tion in the number of organ complications and mortality. 
According to the knowledge of the authors of this paper, 
acquired hemophilia A is considered relatively rare as a cause 
of severe hemorrhage in gynecology and obstetrics.
Acquired hemophilia A (AHA) is an autoimmune dis-
ease caused by autoantibodies that impair the function 
of coagulation factor VIII (FVIII) and lead to a decrease in 
plasma FVIII activity. These antibodies are referred to as 
the circulating FVIII anticoagulant or FVIII inhibitor. Unlike 
congenital hemophilia A, with underlying mutation in the 
F8 gene located on the sex chromosome X, affecting males, 
acquired hemophilia A occurs in both men and women. 
Decrease in FVIII activity in the course of AHA results in 
a tendency to excessive bleeding.
Although acquired hemophilia A is classified as a severe 
bleeding disorder, in about 20–30% of cases it is initially 
manifested by only a minor bleeding, which often can even 
escape the attention of the physician [1]. However, it should 
be clearly stated, that as long as an FVIII inhibitor is detected 
in the patient’s blood, the patient is at risk of experiencing 
a severe, potentially life-threatening hemorrhage. 
Modern medicine has the effective tools to fight AHA, 
that enable control of bleeding, elimination of the inhibitor 
and reduction in mortality. Estimated mortality in the course 
of AHA in the 1980s reached up to 42%, while currently it 
does not exceed 12% [2]. 
The present paper discusses the principles of AHA diag-
nosis, the usage of hemostatic agents for bleeding control 
and prevention, eradication of FVIII inhibitor and patients’ 
surveillance after achieving remission. Particular attention 
was paid to gynecological-obstetrics aspects related to the 
diagnosis and treatment of female patients with AHA.
PATHOPHYSIOLOGY OF ACQUIRED 
HEMOPHILIA A
The key problem in AHA are disorders of the immune 
system resulting in the production of antibodies that neu-
tralize coagulant activity of factor VIII [3]. The mechanisms 
responsible for the breakdown of immune system in AHA 
have not been fully elucidated. The result of deficiency or 
complete absence of FVIII in the plasma is inhibition of 
thrombin generation and the lack of fibrin clot formation 
in sites of the vascular wall damage, which manifests as 
bleeding or hemorrhage.
The autoantibodies produced in acquired hemophilia 
A are mostly IgG1 and IgG4 class and bind to FVIII epitopes 
located on its C2 and A2 domains. The mechanism of their 
anticoagulant action relies on impairment of FVIII interac-
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tion with phospholipids (anti-C2 antibodies), disturbances in 
the formation of the intrinsic tenaze complex (anti-A2 anti-
bodies) and most likely also on blocking the binding of FVIII 
to von Willebrand factor [3, 4]. 
The kinetics of FVIII interaction with autoantibodies in 
AHA is different from the kinetics of FVIII interaction with al-
loantibodies in congenital hemophilia A with inhibitors. While 
in congenital hemophilia A, alloantibodies completely abolish 
the FVIII activity in plasma, in acquired hemophilia A, even with 
a very high titer of autoantibodies, some residual plasma FVIII 
activity is detected. However, it does not protect AHA patients 
from severe bleeding [5]. Similarly to the FVIII alloantibodies, 
also autoantibodies to FVIII do not bind complement and do 
not cause allergic reactions.
EPIDEMIOLOGY
The annual incidence of acquired hemophilia A is esti-
mated at approximately 1.5 per million [6, 7]. The incidence 
of AHA increases with age, amounting to approximately 
0.045/million among children under 16 and 14.7/million 
in people over 85 years of age [6]. The results of the mul-
ti-center, large-scale, pan-European, Web-based Registry 
EACH2 (European Acquired Hemophilia Registry) published 
several years ago, showed that the median age at the time 
of diagnosis of AHA is 73.9 years. In the age range of 20–
40 years, acquired hemophilia A is more often detected in 
women than in men [8]. The increased incidence of AHA 
among young women is closely related to the period of 
pregnancy, especially to the first 6–12 months after delivery 
(see below –Acquired hemophilia associated with pregnancy 
and delivery A). In the older age groups, AHA is slightly more 
often detected in men [1].
Approximately half of patients with detectable autoan-
tibodies against FVIII do not have underlying disorders. This 
form of AHA is called idiopathic. In approximately 35–40% 
of cases, AHA is associated with autoimmune disease, solid 
malignant tumors, hematologic tumors, allergic diseases or 
with a drug exposure (Tab. 1). The remaining 10–15% of cas-
es of acquired hemophilia A are detected, as already men-
tioned, among others, in young women up to 12 months 
after delivery.
CLINICAL MANIFESTATION
In most cases, AHA manifests as a sudden severe bleed-
ing disorder which can lead to the death of a patient within 
a few weeks [1, 9]. Unlike congenital hemophilia A, sponta-
neous bleeding to the joints is very rare in AHA. Typical for 
acquired hemophilia A are large subcutaneous hematomas 
(Fig. 1), mucosal bleeding (from the gastrointestinal and 
genitourinary tract), as well as bleeding from the wounds 
after surgical procedures and after tooth extraction (Tab. 2). 
It is worth noting that in AHA patients the most difficult 
to treat are hemorrhages from the wounds after surgical 
procedures. Therefore, invasive diagnostic and therapeutic 
procedures should be avoided in AHA patients [10]. Intrac-
ranial hemorrhages have a dramatic course and usually fail 
to be stopped on time. Fortunately, this type of bleeding is 
quite rare in patients with AHA. Bleeding to the extremity 
muscles is very dangerous, because hematoma, located in 
a fascia-limited anatomical space, may exert a pressure on 
nerves and blood vessels causing their irreversible injury.
ACQUIRED HEMOPHILIA A ASSOCIATED WITH 
PREGNANCY AND DELIVERY
Acquired hemophilia A is a rare complication of preg-
nancy and postpartum period. It is estimated that there 
is no more than one case of AHA in 350 000 deliveries 
[7]. The disease may occur immediately after delivery, 
manifested by a severe uterine or vaginal hemorrhage, 
Table 1. Underlying disorders predisposing to acquired hemophilia 
development [1]
Underlying condition or disease 
Estimated incidence 
[%]
No underlying condition or disease 
– idiopathic AHA
Malignant tumors
•	 Solid tumors
•	 Hematologic neoplasia
51.9
11.8
8
3.8
Autoimmune diseases 
•	 Rheumatoid arthritis
•	 Other diseases of connective tissue 
•	 Systemic lupus erythematosus 
•	 Autoimmune thyroiditis 
•	 Sjögren syndrome
•	 Antiphospholipid syndrome 
•	 Other autoimmune diseases
11.6
4
1.6
1
0.8
0.6
0.4
3.8
Pregnancy and the period of 12 months 
after delivery 
Infections
Relationship with drug use 
•	 Beta-lactam antibiotics 
•	 Clopidogrel 
•	 Non-beta-lactam antibiotics 
•	 Interferon 
•	 Non-steroidal anti-inflammatory 
drugs 
•	 Amiodarone
•	 Rivastigmine
•	 Sunitinib 
•	 Heparin 
8.4
3.8
3.4
0.8
0.6
0.4
0.4
0.4
0.2
0.2
0.2
0.2
MGUS
Polymyalgia rheumatica 
Dermatological diseases
•	 Psoriasis
•	 Pemphigus 
•	 Others 
2.6
2.2
1.4
0.6
0.6
0.2
Relationship with the transfusion of 
blood products
Other diseases
0.8
8.2
MGUS — monoclonal gammopathy of undetermined significance
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as well as develop up to 12 months after delivery, with 
extensive subcutaneous hematomas as the predominant 
symptom, accompanied by the more or less severe mu-
cosal hemorrhages. The Italian Registry data, published in 
2003, indicate that acquired hemophilia usually develops 
postpartum, after a median of 60 days after delivery [11]. 
In the EACH2 Registry, acquired hemophilia was detected 
within 7 to 355 days (interquartile range [IQR] 21–120 days) 
(a median of 89 days) after delivery and the most com-
mon bleeding pattern was extensive subcutaneous 
hemorrhages (45%), mucosal bleeding (43%), intramus-
cular hematomas or retroperitoneal hemorrhage (33%). 
Only 2 women experienced bleeding into the joints [12]. 
In 45% of women bleeding was spontaneous, and in 55% 
it occurred after trauma [12]. Post-traumatic bleeds were 
predominantly peripartum (34% of all bleeds), and post-
surgical (9% of all bleeds) [12]. Importantly, out of the 
42 women included into the EACH2 Registry, in 8 (19%) 
the symptoms of AHA were present antepartum [12]. Data 
from the EACH2 Registry reveal a significant delay in final 
diagnosis of pregnancy-associated and postpartum AHA. 
The median time between the first symptoms of abnormal 
bleeding and the diagnosis of AHA was 6 days (in every 
fourth women it was 21 days) [12].
Based on published data from about 20 years ago, it 
can be assumed that in about 70% of women with pregnan-
cy-associated/postpartum AHA the spontaneous remission 
of the disease can be expected [13, 14]. However, in the case 
of no remission and a severe course of bleeding disorder, 
an appropriate hemostatic and immunosuppressive treat-
ment should be administered. In the EACH2 Registry, 39 out 
of 42 women with the pregnancy-associated or postpartum 
AHA required immunosuppressive treatment [12]. In the 
opinion of some of clinicians, eradication of the FVIII inhibi-
tor with a use of immunosuppressive drugs in postpartum 
acquired hemophilia A is often more difficult than in the idi-
opathic AHA or in AHA with other underlying conditions [7]. 
This opinion contradicts the results of the EACH2 Registry, 
which show that the use of corticosteroid monotherapy 
led to the eradication of FVIII inhibitor in 74% of women 
with pregnancy-associated AHA, i.e. at no lesser percentage 
than in other groups of AHA patients [12]. 
In the EACH2 Registry, the primigravida accounted for 
74% of all women who developed AHA associated with 
pregnancy and delivery [12]. Additionally, all women with 
pregnancy-associated or postpartum AHA in the EACH2 Reg-
istry were free of other serious diseases or clinical conditions 
Table 2. The incidence of various types of bleeding in AHA [7]
Type of bleeding
Estimated 
incidence [%]
Subcutaneous hematomas (often large) 61
Muscle hematoma 26
Subcutaneous only 13
Gastrointestinal and intraabdominal 13
Genitourinary 5
Retroperitoneal 5
Intraarticular 4
Intracranial < 2
Requiring no hemostatic treatment 20
Figure 1. Large, spontaneous ecchymoses in 2 women with acquired 
hemophilia A (courtesy of the Author)
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that could explain the occurrence of AHA [12]. These data 
are consistent with the results of previous studies. The final 
assessment of the health status in women with pregnancy-as-
sociated or postpartum AHA, in the EACH2 Registry follow-up 
was performed at a median of 406 days (IQR 221–817 days) 
from the onset of AHA symptoms [12]. At that time, all women 
were alive and 36 out of 42 (86%) achieved complete remis-
sion. These results confirm a better prognosis in women with 
pregnancy-associated or postpartum AHA as compared to 
women with AHA associated with other underlying condi-
tions. [12]. The EACH2 registry does not provide information 
on subsequent pregnancies in this group of 42 women. 
One paper describes a decrease in the FVIII activity in 
the blood of a neonate born to a woman with AHA, fol-
lowing transplacental transfer of FVIII antibodies [15]. 
In the newborn occurred a hemorrhage requiring hemo-
static treatment.
LABORATORY FINDINGS
In a person with AHA, laboratory tests typically show 
a 2–3-fold prolongation of activated partial thrombo-
plastin time (aPTT) with normal prothrombin time (PT), 
thrombin time (TT), closure time (CT) in PFA-100/-200® 
(platelet function analyzer), normal platelet count and the 
plasma fibrinogen level within the normal range (Tab. 3). 
Such a combination of laboratory test results is also found 
only in congenital deficiency of clotting factors VIII, IX, XI, 
XII and in the presence of lupus anticoagulant (LA) in the 
test plasma. However, LA is not directed against the clot-
ting factor but against phospholipids and does not trigger 
bleeding but predisposes to thrombosis. If prolonged aPTT 
Table 3. Differential diagnosis of prolonged aPTT
Condition 
                      Parameter 
Coagulation 
times Platelets FIB
Clotting factors activity Mixing 
test*
Inhibitor
 > 0.5 BU/mL
Clinical 
presentation
APTT PT TT FVIII FIX FXI FXII VWF
Acquired hemophilia A ↑ N N N N ↓ N N N N positive FVIII inhibitor
 present
sudden onset of 
bleeding disorder
Hemophilia A ↑ N N N N ↓ N N N N negative absent bleeding disorder
Hemophilia A with 
inhibitors
↑ N N N N ↓ N N N N positive FVIII inhibitor
present
previous treatment 
ineffective 
von Willebrand disease 
type 3
↑ N N N N ↓ N N N ↓ negative absent bleeding disorder
Hemophilia B ↑ N N N N N ↓ N N N negative absent bleeding disorder
Hemophilia B with 
inhibitors
↑ N N N N N ↓ N N N positive FIX inhibitor 
present
previous treatment 
ineffective
FXI deficiency ↑ N N N N N N ↓ N N negative absent bleeding disorder
FXII deficiency ↑ N N N N N N N ↓ N negative absent no symptoms of 
bleeding disorder
Lupus anticoagulant 
(LA)
↑ N N N N
N 
or 
↓#
N 
or 
↓#
N 
or 
↓#
N 
or 
↓#
N positive absent¥
no symptoms of 
bleeding disorder 
/sometimes 
thrombosis
Heparin contamination ↑
N
or
↑
↑ N N
N
or
↓
N
or
↓
N
or
↓
N
or
↓
N positive absent¥
possible symptoms 
of bleeding disorder
Deficiency of Vitamin K 
dependent factors/ 
VKA overdose
N
 or
↑
↑
N
or
↑
N
N
or
↓
N
or
↓
↓
N
or
↓
N
or
↓
N negative absent
possible symptoms 
of bleeding disorder
Severe liver diseases ↑ ↑ ↑ N or ↓ ↓
N
or 
↓
N
or
↓
N
or
↓
N
or
↓
N negative absent
possible symptoms 
of bleeding disorder
DIC
N 
or ↑
N 
or 
↑
N 
or 
↑
↓
N
 or
↓
N 
 or
↓
N 
or
↓
N
or
↓
N
or
↓
N
or
↓
negative absent
possible symptoms 
of bleeding disorder
*) a positive mixing test means the presence of an inhibitor; #) lupus anticoagulant may interfere with assays for coagulation factors activity resulting in falsely lowered 
or elevated values; ¥) lupus anticoagulant and heparins (to a much lesser extent) may interfere with the assays for inhibitor resulting in falsely positive results (inhibitor 
titer > 0.5 BU/mL); ↑ — value above the reference range; ↓ — value below the reference range; aPTT — activated partial thromboplastin time; assays repeated in 
the samples of patient’s diluted plasma allow to exclude the effect of LA; DIC — disseminated intravascular coagulation; F — factor; FIB — fibrinogen; LA – lupus 
anticoagulant; N — value within the reference range; PT — prothrombin time; TT — thrombin time; VKA — vitamin K antagonist; VWF — von Willebrand factor
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is caused by a presence of unfractionated heparin in the 
blood sample, the thrombin time is significantly prolonged 
or non-determinable. Confirmation of the presence of cir-
culating anticoagulant is prolonged aPTT in a mixture of 
equal volumes of the tested plasma and normal plasma 
(no aPTT correction, i.e. a positive test for the presence of 
circulating anticoagulant). A test for the presence of circu-
lating anticoagulant is positive with either FVIII inhibitor 
or LA or an inhibitor directed against coagulation factors 
other than FVIII. Therefore, factor VIII activity should be 
measured, to confirm that the circulating anticoagulant 
is directed against FVIII. FVIII activity in healthy individuals 
is comprised in the range of 50–150 IU/dL (50–150% of 
the normal), while in AHA it is in the range of 0–20 IU/dL. 
The last step to the laboratory diagnosis of the presence 
of FVIII inhibitor is a measurement of its titer expressed in 
Bethesda units (BU/mL) [16–18]. 
It is worth emphasizing that laboratory diagnostics for 
the FVIII inhibitor should be carried out in blood samples 
taken before initiation of hemostatic treatment (see be-
low). Following administration of hemostatic agent, some 
patients with AHA shorten or even normalize aPTT, which 
falsifies the results of subsequent laboratory tests and may 
lead to erroneous exclusion of AHA as a cause of hemor-
rhage (Fig. 2). 
As the diagnostic process of AHA combines the analysis 
of the clinical presentation and the results of specialistic lab-
oratory tests, the authors of this paper indicate the need for 
close cooperation between the medical team and the labo-
ratory diagnostics team in order to optimize this process. 
MANAGEMENT
The treatment strategy in patients with acquired hemo-
philia A has two main goals: immediate, which is control 
and prophylaxis of bleeding, and the ultimate one, which 
is inhibitor eradication i.e. complete remission of AHA, of-
ten meaning the cure (Fig. 2). In rare cases of AHA without 
accompanying symptoms of bleeding disorder, the man-
agement will be limited to the elimination of the inhibitor. 
Prompt diagnosis and appropriate treatment of comorbidi-
ties may increase the chance to achieve AHA remission.
HEMOSTATIC AGENTS
Unlike congenital hemophilia A, there is no close cor-
relation between plasma FVIII activity and the severity of 
bleeding in AHA. Therefore, even with a very low inhibitor 
titer and a few to dozen percent of residual FVIII plasma 
activity, the best way to stop bleeding in AHA is the use of 
so-called by-passing agents (BPA), i.e. recombinant activated 
factor VII (rFVIIa) or activated prothrombin complex con-
centrate (aPCC), but not the administration of human fac-
tor VIII products (hFVIII) (Tab. 4). The BPA activate blood 
clotting, bypassing the factor VIII-dependent stage, hence 
their name: bypassing agents. The efficacy of rFVIIa and 
aPCC in control of bleeding in acquired hemophilia A has 
been confirmed by the results of clinical trials [1, 19–24]. 
The greatest disadvantage of both drugs is the lack of labora-
tory tests to assess their efficacy. The risk of thrombotic com-
plications of both drugs should not be neglected, especially 
in elderly people with concomitant risk factors for venous 
thromboembolism (VTE) and/or arterial thromboembolism 
(ATE). Once the remission is achieved, i.e. the inhibitor is 
eliminated, the use of BPA should be immediately discon-
tinued. Anticoagulants are contraindicated in patients with 
AHA, however, after elimination of the inhibitor, they can be 
safely used if needed. 
In case of a lack of clinical efficacy of rFVIIa and aPCC 
monotherapies, alternating rFVIIa and aPCC (so-called se-
quential therapy) may be used. Sequential therapy exposes 
patients to the risk of thromboembolic complications. There-
fore, it should be only used by a hematologist experienced 
in the treatment of patients with bleeding disorders [25, 26].
Recently, a new medication for bleeding control in AHA - 
recombinant porcine factor VIII (rpFVIII) has been introduced 
[27, 28]. This agent shows the coagulation activity similar to 
human FVIII, and at the same time, in most cases is not neu-
tralized by the antibodies against human FVIII. The biggest 
advantage of rpFVIII as compared to rFVIIa and aPCC is the 
availability of laboratory testing of factor VIII activity in plasma 
of AHA patients and possibility to adjust rpFVIII dose based on 
the results of these measurements. Before switching from BPA 
to rpFVIII, the plasma of the AHA patient should be tested for 
the presence of cross-reactive antibodies, that neutralize both 
hFVIII and rpFVIII. If such antibodies are present, very high doses 
of rpFVIII must be administered and it should be ensured that 
adequate (hemostatic) FVIII activity in the plasma has been 
reached. At the high titer of anti-porcine FVIII antibodies, the 
use of rpFVIII may not be effective. In Poland rpFVIII has been 
approved by regulatory authorities, but so far it is not reim-
bursed by the National Health Fund (NFZ).
In exceptional cases of AHA with a low titer of FVIII 
inhibitor and with a mild bleeding, the use of human FVIII 
concentrate or desmopressin under control of plasma 
FVIII activity may be effective (it is usually recommended 
to maintain FVIII activity above 50 IU/dL). Data from the 
EACH2 Registry indicate that BPA control bleeding much 
more effectively as compared to hFVIII concentrate and 
desmopressin [2, 27, 29, 30].
The drug that effectively controls mucosal bleeding is 
tranexamic acid (TxA). In adults, it is administered at a dose 
of 1.0 g every 8 hours, orally or intravenously (local admin-
istration is less common). The drug is contraindicated in 
people with active bleeding from urinary tract due to the 
risk of clot formation and block of urine outflow. In AHA, 
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tranexamic acid has a status of a supportive treatment. 
It can be used concomitantly with rFVIIa, aPCC, hFVIII and 
rpFVIII. The previously raised concerns about a significant 
increase in the risk of thromboembolic complications in 
patients receiving simultaneously aPCC and TxA have been 
dispelled after publication of positive experiences from 
several research teams [31, 32].
Another treatment option used in AHA patients is the im-
munoadsorption combined with intravenous transfusion of 
high doses of hFVIII concentrate under the control of plasma 
FVIII activity [2]. According to the knowledge of the authors of 
this paper, no immunoadsorption procedures are performed in 
Poland, and literature data indicate that this therapeutic option 
is available in only a few centers in Europe [2].
Therapeutic management for bleeding control in 
a woman with peripartum AHA is the same as in the other 
groups of AHA patients. Data from the EACH2 Registry 
showed high efficacy of BPA in bleeding control in the course 
of AHA associated with pregnancy and delivery [12].
Although, according to the EACH2 Registry data, BPA 
can effectively stop bleeding in more than 93% of patients 
with AHA, it is recommended to avoid elective invasive pro-
Figure 2. Algorithm for management of acquired hemophilia A [10]
aPCC — activated prothrombin complex concentrate; aPTT — activated partial thromboplastin time; hFVIII — human FVIII; FVIII — factor VIII; rFVIIa — recombinant activated factor VII; rpFVIII — re-
combinant porcine factor VIII; 
*) rFVIIa, aPCC, hFVIII and DDAVP concentrates are available free of charge for patients with a confirmed diagnosis of AHA in Regional Blood Donation and Transfusion Centres (RCKiKs); the list of 
RCKiK in Poland is included in the Supplement 2 to this paper
Sudden bleeding disorder  
+ isolated prolonged aPTT 
ﬁ suspect acquired haemophilia
Mild/moderate bleedingSevere bleeding 
Laboratory testing:
•	Mixing	test
•	FVIII	activity
•	Titer	of	FVIII	inhibitor
FVIII inhibitor No
No
Yes
Persistent or 
exacerbating 
bleeding
Further 
diagnostics
Treatment for inhibitor elimination
Start as soon as possible after the 
confirmation of the FVIII inhibitor presence, 
if no contraindications to such treatment
Yes
Treatment of bleeding:
•	 rFVIIa	90	µg/kg	intravenously	every	2-3	h	(first	choice	treatment	in	
many clinical conditions) 
or
•	 aPCC	50-100	U/kg	intravenously	every	8-12	h	(maximum	daily	dose	
of 200 U/kg) 
or
•	 rpFVIII	initially	50-200	U/kg	intravenously,	depending	on	the	
severity of bleeding, further dosing under control of factor VIII 
plasma activity (not reimbursed in Poland) 
until the bleeding stops 
Drugs with uncertain efficacy:  
Desmopressin (DDAVP) and/or high doses of hFVIII concentrate 
provided that hemostatic FVIII activity in plasma is obtained
Supportive treatment:  
Tranexamic acid 3x1.0 g orally or intravenously
Start treatment of bleeding without 
waiting for the test results
Take the blood sample for further diagnostics (CAUTION: 
after administration of rFVIIa, aPCC, rpFVIII, hFVIII and DDAVP 
the aPTT may shorten, which will falsify the results of laboratory 
tests and prevent confirmation of AHA diagnosis)*
•	 Refrain from invasive procedures and surgical opera-
tions that are often complicated by a fatal bleeding
•	 Avoid	aspirin,	non-steroidal	anti-inflammatory	drugs,	
intramuscular injections
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cedures and surgical operations in this group of patients [2]. 
This recommendation comes from the observation that de-
spite the use of optimal anti-hemorrhagic treatment, invasive 
procedures (including catheterization of large blood vessels) 
in patients with AHA may be complicated by a massive, un-
controlled, potentially life-threatening bleeding. However, 
if the delay in conducting an invasive procedure or surgical 
operation is medically unacceptable, the management for 
perioperative period should be consulted with a hematolo-
gist who has expertise in the treatment of bleeding disorders. 
The BPA posology in this situation does not differ from the BPA 
posology for the invasive procedures conducted in patients 
with congenital hemophilia A with FVIII inhibitors [25].
According to regulations of the National Program for 
Treatment of Hemophilia and Allied Bleeding Disorders 
(2019–2023) in Poland, rFVIIa, aPCC, hFVIII concentrates, as 
well as desmopressin are available free of charge for the treat-
ment of patients with a confirmed AHA diagnosis from the 
Regional Blood Donation and Transfusion Centers (Region-
alne Centrum Krwiodawstwa i Krwiolecznictwa, RCKiK) [33]. 
The list of RCKiK is included in Appendix 1 to this article. 
INHIBITOR ERADICATION
In order to eliminate autoantibodies against FVIII, im-
munosuppressive drugs are used [2, 9, 11, 27, 29, 30, 34]. 
Immunosuppressive treatment should be initiated as soon 
as the diagnosis of acquired hemophilia A is confirmed, 
although the possible contraindications to this type of treat-
ment should never be ignored. It also should not be forgot-
ten that immunosuppressive therapy carries a considerable 
risk of side effects, including myelosuppression and serious 
infections, which are particularly dangerous in the elderly 
patients, who constitute the majority of patients with ac-
quired hemophilia A. Nonetheless, in the EACH2 Registry, 
also three young women with pregnancy-associated or 
postpartum AHA developed complications after immuno-
suppression — two patients had post-steroid diabetes, and 
one suffered from infection [12].
The majority of authors recommends corticosteroids or 
corticosteroids with cyclophosphamide in the first-line of 
immunosuppressive therapy (Tab. 5) [1, 2, 9, 11, 27, 29, 30, 
34–39]. There is usually given prednisone/prednisolone oral-
ly at a dose of 1 mg/kg/day for 4–6 weeks in monotherapy or 
in combination with cyclophosphamide also orally at a dose 
of 1–2 mg/ kg/day, for a maximum of 6 weeks. With the use of 
such treatment regimen remission, defined as an increase in 
FVIII activity above 50 IU/dL and lowering the inhibitor titer 
below the detection threshold, i.e. 0.6 BU/mL, is achieved 
in about 70% of patients. In the EACH2 Registry, at the end 
of follow-up, after a median of 258 days (IQR 74–685 days) 
72.6% of patients with AHA achieved complete remission 
of disease, 11.8% of patients normalized FVIII activity, but 
continued immunosuppressive therapy, 10% of patients 
failed to eliminate FVIII inhibitor, and in 6.6% of patients 
the status of FVIII inhibitor was unknown [1]. 
In patients who have not achieved remission after 
4–6 weeks of immunosuppressive treatment, a second 
attempt to eliminate the inhibitor is recommended. Cur-
rently, the prevailing opinion is that in the second-line of 
immunosuppressive treatment it is worth using rituximab 
at a standard dose of 375 mg/m2/week for the consecutive 
4 weeks (smaller doses have also been successfully used) 
[40, 41]. Unfortunately, the use of rituximab in patients with 
AHA is not covered by the NFZ reimbursement in Poland. 
Other therapeutic options include the use of ciclosporin, 
tacrolimus, azathioprine, vincristine and mycophenolate 
mofetil, as well as a combination therapy including sev-
eral immunosuppressants administered concomitantly, 
Table 4. Drugs used to control bleeding in acquired hemophilia A 
Drug Posology
rFVIIa
≥ 90 mg/kg i.v. every 2–3 h in case of severe bleeding, with an option to subsequently extend dosing 
intervals up to 4–6–12–24 h
aPCC 50–100 U/kg i.v. every 8–12 h (maximum of 200 U/kg/day)
rpFVIII
If anti-rpFVIII antibodies absent: initially 50–100 U/kg, further dosing under the control of plasma FVIII 
activity*; 
If anti-rpFVIII antibodies present: initially 200 U/kg in the severe bleeding or 50–100 U/kg in the milder 
bleeding, further dosing under the control of plasma FVIII activity*; 
Human factor VIII+ concentrate
50–100 U/kg i.v. every 8–12 h or in a continuous intravenous infusion under the control of plasma factor 
VIII activity
Desmopressin+
0.3–0.4 mg/kg (in 100 mL 0.9% NaCl) in an intravenous infusion over a minimum of 30 min, repeated, if 
necessary, every 24 h under the control of plasma factor VIII activity 
Tranexamic acid (supportive treatment) 1.0 g every 8 h orally or intravenously
+) drugs with uncertain efficacy and limited use in acquired hemophilia A;  
*) the measurement of plasma porcine FVIII activity should be performed frequently, i.e. every 2–3h especially in the initial phase of treatment and when the bleeding is 
severe; aPCC — activated prothrombin complex concentrate; i.v. — intravenously; rFVIIa — recombinant activated factor VII; rpFVIII — recombinant porcine factor VIII; 
i.v. — intravenously
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e.g. cyclophosphamide + vincristine + prednisone [42–46]. 
In the opinion of some investigators, the combined use of 
immunosuppressive drugs and intravenous injections of 
hFVIII concentrate contributes to the shortening of time 
needed to eliminate the inhibitor. This treatment regimen, 
elaborated by the Hungarian authors and based on the 
immunotolerance programs used in congenital hemophilia 
A with alloantibodies developed against FVIII, is referred to 
as the Budapest Program (Tab. 5) [47].
The management targeted on elimination of FVIII inhibi-
tor in a woman with the postpartum AHA is based on the 
same principles as in the other groups of AHA patients with 
one exception; in young patients at childbearing age, the use 
of cytotoxic drugs (e.g. cyclophosphamide) is avoided [2, 12]. 
Data from the EACH2 Registry showed a high efficacy of 
immunosuppressive drugs (including corticosteroid mono-
therapy) in eliminating FVIII inhibitor in AHA associated with 
pregnancy and delivery [12].
FOLLOW-UP AFTER COMPLETE REMISSION
After achieving remission, the patient should be fol-
lowed-up for two years for possible relapse [2, 27, 29, 30]. 
FVIII activity should be measured once a month for the 
first six months after remission, then every 2–3 months 
for the next six months and then every 6 months for the 
following year. It is estimated that AHA relapse occurs in 
about 20% of patients who achieved remission after the 
first course of immunosuppressive treatment [5]. In such 
cases, second attempt to eliminate the inhibitor should be 
taken and the same immunosuppressive treatment that 
provided the first remission can be used. If immunosup-
pressive therapy completely fails, a careful monitoring and 
treatment of hemorrhage is the only management option. 
In case of high severity of bleeding disorder, prolonged 
prophylaxis with use of inhibitor bypassing agents can be 
considered [23, 48].
Older studies did not show AHA recurrence in subse-
quent pregnancies, but recently such cases have been de-
scribed [14, 49–51]. Therefore, if a woman with a history 
of pregnancy-associated or postpartum AHA is planning 
another pregnancy, she should be covered by a specialist 
care of gynecologist and hematologist, to ensure moni-
toring of hemostasis system for prompt detection of FVIII 
inhibitor recurrence. 
PROGNOSIS FOR SURVIVAL IN ACQUIRED 
HEMOPHILIA A
Prognosis in AHA depends on the type and course of 
comorbidities, on the severity of bleeding and on the time 
to diagnosis and initiation of appropriate anti-hemorrhagic 
and immunosuppressive treatment [30].
In the EACH2 Registry, the survival analysis included 
a group of 331 patients with AHA. The median follow-up 
was 258 days (IQR 74–685 days). The final analysis showed 
that 61.2% of patients survived, 27.9% died, with a me-
dian of time between AHA diagnosis and death being 75 days 
(IQR 25–240 days). For 10.9% of patients the survival status 
remained unknown [1]. Data from this registry identified the 
independent risk factors for death in AHA patients: older age, 
lower hemoglobin level at the AHA diagnosis, concomitant 
malignancy, and failure to eliminate FVIII inhibitor [1]. In con-
trast, gender, FVIII activity at the time of AHA diagnosis and 
Table 5. Drugs used to eliminate autoantibodies against Factor VIII
Drug Suggested posology
Prednisone/Prednisolone* 1 mg/kg/d orally for a maximum of 4–6 weeks
Cyclophosphamide* 1.5–2.0 mg/kg/d orally for a maximum of 4–6 weeks
Rituximab 375 mg/m2 intravenously once a week (for ≥ 4 consecutive weeks) (lower doses may be effective)
Azathioprine 2 mg/kg/d orally (maximum daily dose of 150 mg)
Cyclosporine 
5 mg/kg/d orally for 6 days, followed by 2.5–3 mg/kg/d orally under the control of serum concentration, which should 
be 100–200 ng/mL
IVIg+ 0.3–0.4 g/kg/d intravenously for 5 days or 1 g/kg/d intravenously for 2 days
Vincristine # 1 mg/m2 intravenously (maximum single dose of 2 mg), 4-6 infusions in 7-day intervals (maximum total dose of 6 mg)
2-CDA 0.1 mg/kg in a 24-hour infusion over 7 days or 0.14 mg/kg in a 2-hour intravenous infusion for 5 days
Mycophenolate mofetil 1000 mg every 12 h orally for at least 3–4 weeks
Immunotolerance
(Budapest Program)
FVIII intravenously 30 IU/kg every 24 h for the first week, 20 IU/kg every 24 h for the second week and 15 IU/kg every 
24 h for the third week 
+ cyclophosphamide (intravenously) 200 mg/d for a total dose of 2-3 g
+ methylprednisolone (intravenously) 100 mg/d for the first week and in gradually decreasing doses over the next 
two weeks
*) in the first-line treatment it is recommended to use prednisone or prednisolone in a combination with cyclophosphamide at the doses shown in the table; #) 
most often in a combination with cyclophosphamide and/or prednisone; +) monotherapy is not recommended; 2-CDA — 2-chlorodeoxyadenosine; d — day; 
IVIg—– intravenous immunoglobulins; FVIII — factor VIII
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FVIII inhibitor titer at the time of AHA diagnosis did not show 
a statistically significant effect on the patients’ survival [1]. 
Death due to a bleeding occurred in 3% of patients 
followed in the EACH2 Registry [1]. Interestingly, excessive 
bleeding was the cause of (only) 16% of all deaths in the ana-
lyzed group. The most frequent cause of death in this group 
was underlying disease, responsible for 45% of all deaths 
(9% of patients in the follow-up of the EACH2 Registry). 
Complications of immunosuppression, similarly to hemor-
rhages, were responsible for deaths of 3% of all patients 
followed in the EACH2 Registry. 
SUMMARY
The cardinal principles of diagnostic and therapeutic 
approach in AHA are presented below: 
1. A sudden onset of bleeding disorder accompanied by 
an isolated prolonged aPTT in a person with no previous 
history of bleeding should raise a suspicion of acquired 
hemophilia A.
2. Acquired hemophilia A affects, most of all, elderly people 
and patients with autoimmune diseases or malignan-
cies, but young women up to 12 months after delivery 
are also at higher risk of developing AHA.
3. In young women diagnosed with autoimmune disease, 
the possibility of occurrence of AHA in the peripartum 
period should be taken into consideration and a patient 
should be offered a care of the facility capable to moni-
tor hemostasis system throughout a pregnancy, delivery 
and postpartum period. 
4. Irrespective of age, in women with autoimmune disease 
and malignancy that experience prolonged uterine or 
vaginal bleeding, the possibility of AHA should be con-
sidered and basic coagulation tests should be done. 
Once the isolated prolonged aPTT is found, the diag-
nostic panel for AHA should be conducted. 
5. Although AHA is classified as a severe bleeding disorder, 
in about 30% of cases the symptoms of the disease 
are occult or scarce, which may hinder establishing 
promptly a proper diagnosis. 
6. Laboratories of hemostasis should develop and apply 
in their daily practice the algorithms for detection of 
isolated prolonged aPTT. This algorithms should in-
clude the clinical presentation (presence or absence 
of symptoms of bleeding disorder) and the mixing test 
of examined and normal plasma for an aPTT correction, 
which indicates the presence or absence of a circulating 
anticoagulant. 
7. Invasive procedures and surgical operations expose AHA 
patients to the risk of uncontrolled hemorrhage, even 
when using appropriate hemostatic drugs at proper 
doses. Therefore, it is recommended to avoid all elective 
invasive procedures in this group of patients until the 
FVIII inhibitor is eliminated. If a delay in invasive proce-
dure is not possible, the anti-hemorrhagic management 
should be decided by a hematologist experienced in the 
treatment of bleeding disorders. 
8. The strategy for management of AHA patient includes 
bleeding control, elimination of FVIII inhibitor and treat-
ment of comorbidities, first of all those that predispose 
to a development of FVIII inhibitor. 
9. The first-line hemostatic drugs are inhibitor bypass-
ing agents, i.e. rFVIIa and aPCC. Desmopressin and hu-
man factor VIII concentrate are less effective than by-
passing agents. Recombinant porcine factor VIII is not re-
imbursed by National Health Fund in Poland. Tranexamic 
acid is a supportive drug. Posology of hemostatic drugs 
is shown it the Table 4.
10. In case of a lack of clinical efficacy of rFVIIa and aPCC mono-
therapies, alternating rFVIIa and aPCC (so-called sequential 
therapy) may be used. Sequential therapy exposes patients 
to the risk of thromboembolic complications. Therefore, it 
should be only used by a hematologist experienced in the 
treatment of patients with bleeding disorders. 
11. The FVIII inhibitor should be eliminated by using immu-
nosuppressive drugs in every patient with AHA (unless 
the inhibitor has been eliminated spontaneously). Im-
munosuppressive treatment should be initiated as soon 
as possible after the AHA is diagnosed, provided there 
are no contraindications to this therapy.
12. In the first-line of immunosuppressive treatment, corti-
costeroids are used, most often prednisone/predniso-
lone orally at a dose of 1 mg/kg/day. Sometimes pred-
nisone/prednisolone is used in combination with cyclo-
phosphamide from the very beginning of treatment, 
however the latter one should not be administered in 
patients at childbearing age. In the second-line treat-
ment for elimination of FVIII inhibitor in AHA rituximab 
is the most commonly prescribed drug; unfortunately, in 
this indication rituximab is not covered by the NFZ reim-
bursement. Posology of immunosuppressive drugs used 
in the treatment of AHA patients is shown in Table 5.
13. Care for a woman with pregnancy-associated or postpar-
tum AHA should be taken by a team consisting of a gy-
necologist-obstetrician and a hematologist experienced 
in the treatment of patients with bleeding disorders. 
14. The principles of treatment of a woman with pregnan-
cy-associated and postpartum AHA do not differ from 
the principles of treatment in other groups of patients 
with AHA. This applies to the use of both hemostatic and 
immunosuppressive drugs. The only exception is the 
avoidance of cyclophosphamide and other alkylating 
drugs in women at childbearing age. 
15. The AHA may recur, therefore, after successful FVIII in-
hibitor elimination, aPTT and plasma FVIII activity should 
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Appendix 1. The list of Regional Blood Donation and Transfusion Centers (Regionalne Centrum Krwiodawstwa i Krwiolecznictwa, RCKiK)
Name Address Contact
Regional Blood Donation and Transfusion Center in Białystok Marii Skłodowskiej-Curie 23, 15-950 Białystok tel. 85 744 70 02
Regional Blood Donation and Transfusion Center in Bydgoszcz Ks. Markwarta 8, 85-015 Bydgoszcz tel. 52 322 18 71
Regional Blood Donation and Transfusion Center in Gdańsk J. Hoene-Wrońskiego 4, 80-210 Gdańsk tel. 58 520 40 20
Regional Blood Donation and Transfusion Center in Słupsk Szarych Szeregów 21, 76-200 Słupsk tel. 59 842 20 21
Regional Blood Donation and Transfusion Center in w Katowice Raciborska 15, 40-074 Katowice tel. 32 208 73 00
Regional Blood Donation and Transfusion Center in Racibórz Sienkiewicza 3 A, 47-400 Racibórz tel. 32 418 15 92
Regional Blood Donation and Transfusion Center in Kielce Jagiellońska 66, 25-734 Kielce tel. 41 335 94 00
Regional Blood Donation and Transfusion Center in Kraków Rzeźnicza 11, 31-540 Kraków tel. 12 261 88 20
Regional Blood Donation and Transfusion Center in Lublin Żołnierzy Niepodległej 8, 20-078 Lublin tel. 81 532 62 75
Regional Blood Donation and Transfusion Center in Łódź Franciszkańska 17/25, 91-433 Łódź tel. 42 616 14 00
Regional Blood Donation and Transfusion Center in Olsztyn Malborska 2, 10-255 Olsztyn tel. 89 526 01 56
Regional Blood Donation and Transfusion Center in Opole Kośnego 55, 45-372 Opole tel. 77 441 06 00
Regional Blood Donation and Transfusion Center in Poznań Marcelińska 44, 60-354 Poznań tel. 61 886 33 00
Regional Blood Donation and Transfusion Center in Kalisz Kaszubska 9, 62-800 Kalisz tel. 62 767 66 63
Regional Blood Donation and Transfusion Center in Rzeszów Wierzbowa 14, 35-310 Rzeszów tel. 17 867 20 30
Regional Blood Donation and Transfusion Center in Szczecin Al. Wojska Polskiego 80/82, 70-482 Szczecin tel. 91 424 36 00
Regional Blood Donation and Transfusion Center in Warszawa Saska 63/75, 03-948 Warszawa tel. 22 514 60 00
Blood Donation and Transfusion Center of the Ministry of Internal 
Affairs and Administration
Wołoska 137, 02-507 Warszawa tel. 22 508 13 12
Military Blood Donation and Transfusion Center Koszykowa 78, 00-671 Warszawa tel. 26 184 50 66
Regional Blood Donation and Transfusion Center in Radom Limanowskiego 42, 26-600 Radom tel. 48 340 05 20
Regional Blood Donation and Transfusion Center in Wrocław Czerwonego Krzyża 5-9, 50-345 Wrocław tel. 71 371 58 10
Regional Blood Donation and Transfusion Center in Wałbrzych Chrobrego 31, 58-303 Wałbrzych tel. 74 664 63 10
Regional Blood Donation and Transfusion Center in Zielona Góra Zyty 21, 65-046 Zielona Góra tel. 68 329 83 60
be checked every month for the first 6 months, every 
2–3 months for the next six months, and then every 
6 months in the second year of follow-up. 
16. Anticoagulants are contraindicated in a patient with 
AHA. After eliminating FVIII inhibitor and achieving AHA 
remission, in case of thromboembolism anticoagulants 
should be used according to generally accepted prin-
ciples of therapy. 
17. In case a woman with a history of pregnancy-associated 
and postpartum AHA is planning another pregnancy, 
she should be covered by specialist care of gynecologist 
and hematologist, to ensure monitoring of hemostasis 
system for prompt detection of the FVIII inhibitor recur-
rence. Management of the AHA relapse is the same as 
in the first AHA episode.
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